DYRK1A is a novel target in B-cell leukemia

Project: Research project

Project Details


Pre-B cell acute lymphoblastic leukemia (ALL) is a relatively common childhood cancer, which has an increased incidence in children with Down syndrome. Although the majority of children with B-ALL survive, they suffer many debilitating side effects from the treatment, and in some cases the disease returns. We are performing experiments to identify new drug targets, such as a protein named DYRK1A, which control the activity and level of other important proteins. In addition, we are testing whether molecules that block the activity of DYRK1A show anti-leukemia activity with the goal of bringing these drugs to clinical trials.
Effective start/end date4/1/156/30/16


  • Rally Foundation, Inc. (AGMT- 4/17/15)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.